Search results:
Search results from www.aesgp.eu
| Ingredient | ATC Level 1 | ATC Level 2 | Year Of Switch | Country | Status | Additional Information |
|---|---|---|---|---|---|---|
| Fluoride (sodium) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A01. Stomatological preparations | 1998 | Canada | OTC | Regulated as a natural health product. |
| Hexetidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A01. Stomatological preparations | — | Canada | N.R. | Not registered or not marketed. |
| Aluminium hydroxide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | N.R. | Not registered or not marketed. |
| Calcium carbonate | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | OTC | Regulated as a natural health product. |
| Carbenoxolone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | Rx | — |
| Cetraxate | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | N.R. | Not registered or not marketed. |
| Cimetidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 1997 | Canada | OTC | When sold in concentrations of 200 mg or less per oral dosage unit and indicated for the treatment of heartburn. 100mg switched in 1997, 200mg switched in 2000. |
| Famotidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 1996 | Canada | OTC | For the treatment & prevention of acid-related gastrointestinal symptoms in adults and children over 12 years of age. Dosage is 10mg per tablet, Maximum Daily Dose is 20mg (treatment should not exceed two weeks). 20 & 40mg dosages switched in 2007. |
| Lansoprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | Rx | — |
| Nizatidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 1998 | Canada | OTC | Nizatidine 75mg, for the symptomatic treatment of heartburn and acid indigestion. |
| Omeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2014 | Canada | OTC | OTC when indicated for a 14-day treatment of frequent heartburn at a daily dose of 20mg. |
| Pantoprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | Rx | — |
| Rabeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | Rx | — |
| Ranitidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 1997 | Canada | OTC | 75mg or less per dosage unit, for symptomatic treatment of heartburn and acid indigestion. 150mg dosage switched in 2007. |
| Sucralfate | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Canada | Rx | — |
| Dicyclomine (Dicycloverine) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | 1998 | Canada | OTC | Ethical OTC status (medicine which does not require a prescription but is generally prescribed by a medical practitioner). |
| Dimeticone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | Canada | N.R. | Not registered or not marketed. |
| Domperidone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | Canada | Rx | — |
| Hyoscine butylbromide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | 2016 | Canada | OTC | Injectable hyoscine butylbromide has been reverse-switched to prescription status from ethical OTC status (medicine which does not require a prescription but is generally prescribed by a medical practitioner). Oral hyoscine butylbromide remains ethical OTC status. |
| Mebeverine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | Canada | N.R. | Not registered or not marketed. |
| Metoclopramide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | Canada | Rx | — |
| Propantheline | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | Canada | N.R. | Not registered or not marketed. |
| Dimenhydrinate (diphenhydramine and 8-chlorotheophylline) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A04. Antiemetics and antinauseants | 1999 | Canada | OTC | — |
| Hyoscine (Scopolamine) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A04. Antiemetics and antinauseants | 2016 | Canada | OTC | Ethical OTC status (medicine which does not require a prescription but is generally prescribed by a medical practitioner). |
| Hymecromone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A05. Bile and liver therapy | — | Canada | N.R. | Not registered or not marketed. |
| Bisacodyl | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | 2014 | Canada | OTC | OTC in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl . |
| Lactitol | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | — | Canada | OTC | No product currently marketed. |
| Lactulose | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | — | Canada | OTC | 667mg/ml. |
| Macrogol (Polyethylene glycol 3350) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | — | Canada | OTC | Macrogol is OTC in 15% lubricating nasal gel, 15% lubricating nasal mist and 160mg/ml nasal lubricant. |
| Picosulfate (sodium) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | — | Canada | OTC | Ethical OTC status (medicine which does not require a prescription but is generally prescribed by a medical practitioner). |
| Loperamide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A07. Antidiarrheals, intestinal antiinflammatory/antiinfective agents | 1986 | Canada | OTC | — |
| Nifuroxazide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A07. Antidiarrheals, intestinal antiinflammatory/antiinfective agents | — | Canada | N.R. | Not registered or not marketed. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Canada | Rx | — |
| Vitamin A (Retinol) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A11. Vitamins | — | Canada | OTC | Vitamin A is regulated as a natural health product, except in oral dosage forms containing more than 10,000 IU of Vitamin A, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 IU of Vitamin A. |
| Selenium | A Alimentary tract and metabolism. Alimentary tract and metabolism | A12. Mineral supplements | 2003 | Canada | OTC | Regulated as a natural health product. |
| Tranexamic acid | B Blood and blood forming organs. Blood and blood forming organs | B02. Antihemorrhagics | — | Canada | Rx | — |
| Adenosine | C Cardiovascular system. Cardiovascular system | C01. Cardiac therapy | 2013 | Canada | OTC | Unless sold or recommended for administration by IV injection, Adenoside-containing products are regulated as natural health products. |
| Nitro-glycerine | C Cardiovascular system. Cardiovascular system | C01. Cardiac therapy | — | Canada | OTC | Ethical OTC status (medicine which does not require a prescription but is generally prescribed by a medical practitioner). |
| Ubidecarenone | C Cardiovascular system. Cardiovascular system | C01. Cardiac therapy | — | Canada | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | 2014 | Canada | OTC | Maximum daily dose 1mg. |
| Simvastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Canada | Rx | — |
| Amorolfine (topical) | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | Canada | N.R. | Not registered or not marketed. |
| Bifonazole | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | Canada | N.R. | Not registered or not marketed. |
| Butenafine | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | 1999 | Canada | OTC | 1% cream. |
| Ciclopirox Olamine | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | Canada | Rx | — |
| Clotrimazole (topical) | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | 1994 | Canada | OTC | General sale. |
| Croconazole | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | Canada | N.R. | Not registered or not marketed. |
| Econazole (topical) | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | Canada | N.R. | Not registered or not marketed. |
| Fenticonazole (topical) | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | Canada | N.R. | Not registered or not marketed. |
| Fluconazole | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | 2010 | Canada | OTC | Non-prescription status for 150mg of fluconazole for oral use in the treatment of vaginal candidiasis. |
- Page 1 of 6
- Next
- 50 of 262 ingredients